Nov 3, 2025 | GLP-1s, MedBen Rx, Obesity, Weight loss, Weight loss drugs, Weight management
A recent International Foundation of Employee Benefit Plans survey shows that while employers are open to covering GLP-1 drugs for diabetes, they’re far more hesitant to do so for weight loss. Over half of corporate and multiemployer/public plans cover GLP-1s for...
Jun 10, 2024 | Affordable Care Act, Caroline Fraker, MedBen Rx, Obesity, Wegovy, Weight loss, Weight loss drugs, Zepbound
While most health plans do not currently cover obesity medications like Wegovy and Zepbound – and MedBen Rx recommends clients continue not to do so – constant media coverage means the calls to do so will only grow. Therefore, employers are increasingly considering...
Apr 11, 2024 | American Heart Association (AHA), Heart, MedBen WellLiving, Obesity, Primary Care, Research, Wellness, Wellness exam
Regular primary care visits are crucial to preventing chronic heart conditions, a new study of personal health habits suggests. Jeremy Sussman of the University of Michigan Department of Internal Medicine said, “As a society, we need to recognize that preventing...
Nov 14, 2023 | Drug costs, Obesity, Pharmacy, Prescription, Wegovy, Weight loss, Zepbound
In light of all the attention that weight loss drugs have received lately – as well as the pricing havoc these drugs have been causing in some pharmacy plans – the following news items have caught our attention: North Carolina says its health plan will...
Jun 15, 2023 | Obesity, Ozempic, Pharmacy, Prescription, Rx Costs, Semaglutide, Wegovy, Weight loss
Obesity drugs are becoming big business, with a correspondingly big price tag. And with these drugs regularly making headlines, questions about whether or not health plans should cover them grow louder. The highest-profile obesity drug is semaglutide, sold under the...
Dec 8, 2022 | Diabetes, Obesity, Prescription
The latest “Hollywood weight-loss drug” has generated interest for its pound-shedding potential, but doctors caution that its benefits should be measured against other factors. Approved by the FDA in 2017 for type 2 diabetes treatment, Semaglutide...
